As physicians turn to mammography as a more reliable way to diagnose breast cancer, a new study shows that the screening method does not reduce the number of deaths from the disease and could lead to overdiagnosis, suggesting a few kinks in the system.
Dalantercept (ACE-041) is owned by Acceleron and is currently in early clinical trials for liver and kidney carcinomas. More recently, though, researchers at Lund University demonstrated that it could block the activin receptor-like 1 (ALK1) pathway, suggesting it may also slow metastasis in aggressive breast cancer.
Scientists from Cincinnati Children's Hospital Medical Center report that the best way to prevent breast cancer from growing resistant to therapies may be to genetically strip cancer cells' natural defenses against intrinsic stress.
Just as the latest breast tomosynthesis equipment option has made it through the FDA with an approval for Siemens, startup VuComp has submitted its own PMA to gain approval for its computer-aided detection software for digital breast tomosynthesis images.
Investigators believe that they have found a new approach to treating HER2-positive breast cancer in a class of enzymes called protein tyrosine phosphatases, or PTPs, which plays a role in cell proliferation.
According to a new report, the U.S. wastes as much as $4 billion a year in unnecessary medical costs that are the result of mammograms that produce false positives, and treatments of certain breast tumors that aren't life-threatening.
About two months ago, Nektar was talking up a big expansion, making way for the new staffers that would be needed to start commercializing the breast cancer drug NKTR-102. Today, the biotech may be rethinking that plan, as the drug failed in a pivotal late-stage study.
Researchers at The University of Texas MD Anderson Cancer Center say they've devised a new strategy for attacking breast cancer tumors before they metastasize.
Koning has gained a PMA approval for the first 3-D breast computed tomography scanner to extensively image the breast without compressing it.
Cancer drug researchers have developed some major new drugs for treating HER2-positive breast cancer, but patients still develop resistance to them. Now a team at Dartmouth says it has identified a key pathway for resistance that points to a new class of third-line therapies.